NCT00487747View on ClinicalTrials.gov

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions

Hepatitis B, Chronic

Interventions

DRUG

peginterferon alfa-2a [Pegasys]

180 micrograms sc weekly for 48 weeks

Trial Locations (23)

111020

Moscow

115516

Moscow

121293

Moscow

123367

Moscow

190103

Saint Petersburg

344010

Rostov-on-Don

355017

Stavropol

400138

Volgograd

420097

Kazan'

443021

Samara

450000

Ufa

454052

Chelyabinsk

603022

Nizhny Novgorod

620020

Yekaterinburg

620102

Yekaterinburg

625002

Tyumen

630016

Novosibirsk

634050

Tomsk

654063

Novokuznetsk

660049

Krasnoyarsk

664047

Irkutsk

677000

Yakutsk

Unknown

Moscow

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00487747 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B. | Biotech Hunter | Biotech Hunter